Skinuvita
Skinuvita provides a mobile app for supervised home phototherapy treatment for psoriasis and dermatitis, enabling patients to undergo established medical therapy from home with doctor oversight.
Classification
Profile
Funding
Funding details not yet available.
Compliance
Home-based phototherapy for psoriasis and dermatitis, supervised by doctors via app, delivering 82% success rate and improved quality of life.
Patients suffering from psoriasis and atopic dermatitis seeking convenient, effective home treatment options.
hardware sales, services
Direct-to-consumer via mobile app, enabling complete therapy management from home.
Medical professionals who supervise patient therapy remotely through the company's application platform.
R&D, hardware manufacturing, clinical compliance, sales
Proprietary app platform for remote medical supervision and established phototherapy treatment protocols.
Providing remote medical supervision, managing the therapy app, and ensuring treatment efficacy and safety.
Doctor-supervised service delivered through a digital app, focusing on long-term therapy management and quality of life.
Differentiates by bringing established phototherapy home with remote medical supervision, avoiding clinic visits.
Inconvenience of clinic visits for chronic skin conditions and need for effective, high-success-rate home treatments.
- Expand payer network - Negotiate blanket reimbursement contracts with additional statutory Kassen (e.g., Techniker TK, Barmer) to increas
- Map current insurer contracts - Create a spreadsheet of existing Kassen agreements, reimbursement rates, and renewal dates · How can Skinuvita monetize anonymised outcome data while staying GDPR-compliant? · What are the barriers for private insurers to adopt a reimbursement model for home UV-B therapy?
The app channel enables direct revenue from hardware and services while facilitating the key activity of remote medical supervision.
- Regulatory compliance - The device is CE-marked Class IIa and listed on multiple insurer pilot pages, confirming medical-device legitimac
Team details not yet available.
No investors recorded yet.